Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

Exclusion Criteria

• •History of gastroparesis
• •History of celiac disease
• •Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
• •Microscopic colitis, including collagenous colitis
• •Has taken linaclotide within 30 days prior to consent
• •Any malignancy except colorectal cancer or any active radiotherapy or cytotoxic chemotherapy within the last 6 months of baseline. Participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator
• •Participants may not be receiving any other investigational agents, or be active participants in any clinical trials. If participants previously participated in a clinical trial, a 30 day washout period for the investigational drug is needed before the participant can be considered for this study
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to linaclotide
• •Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Pregnant or lactating women
• •History of bleeding/coagulation problems. Concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin is acceptable
• •Any medical condition judged by the investigator to constitute a risk to safe participation
• •At risk for obstructing or near-obstructing mechanical gastrointestinal obstruction
• •Chronic use of anti-coagulants or non-NSAID anti-platelet agents will serve as an exclusion only when such medications cannot be safely discontinued before study related endoscopy or surgery